IL97545A - Monoclonal antibodies and other binding molecules against CD25 antigen - Google Patents
Monoclonal antibodies and other binding molecules against CD25 antigenInfo
- Publication number
- IL97545A IL97545A IL9754591A IL9754591A IL97545A IL 97545 A IL97545 A IL 97545A IL 9754591 A IL9754591 A IL 9754591A IL 9754591 A IL9754591 A IL 9754591A IL 97545 A IL97545 A IL 97545A
- Authority
- IL
- Israel
- Prior art keywords
- antigen
- binding molecules
- monoclonal antibodies
- antibodies
- molecules against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909005962A GB9005962D0 (en) | 1990-03-16 | 1990-03-16 | Improvements in or relating to organic compounds |
GB909019323A GB9019323D0 (en) | 1990-09-05 | 1990-09-05 | Improvements relating to immunosuppression |
Publications (2)
Publication Number | Publication Date |
---|---|
IL97545A0 IL97545A0 (en) | 1992-06-21 |
IL97545A true IL97545A (en) | 2000-06-29 |
Family
ID=26296798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL9754591A IL97545A (en) | 1990-03-16 | 1991-03-14 | Monoclonal antibodies and other binding molecules against CD25 antigen |
Country Status (23)
Country | Link |
---|---|
US (2) | US6521230B1 (fi) |
EP (1) | EP0449769B1 (fi) |
JP (1) | JP2585475B2 (fi) |
AT (1) | ATE98655T1 (fi) |
AU (1) | AU635401B2 (fi) |
CA (1) | CA2038279C (fi) |
CY (1) | CY1977A (fi) |
DE (2) | DE19975033I2 (fi) |
DK (1) | DK0449769T3 (fi) |
ES (1) | ES2061216T3 (fi) |
FI (3) | FI103131B1 (fi) |
HK (1) | HK53797A (fi) |
HU (2) | HUT60768A (fi) |
IE (1) | IE65062B1 (fi) |
IL (1) | IL97545A (fi) |
LU (1) | LU90383I2 (fi) |
MY (1) | MY106161A (fi) |
NL (1) | NL990008I2 (fi) |
NZ (1) | NZ237434A (fi) |
PL (1) | PL170321B1 (fi) |
PT (1) | PT97034B (fi) |
SA (1) | SA92120358B1 (fi) |
TW (1) | TW213486B (fi) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
JPH07509444A (ja) * | 1991-11-26 | 1995-10-19 | アルカーメス・インコーポレーテツド | トランスフェリンセレプター特異的抗体−神経薬又は診断薬複合体の製造法 |
US6024957A (en) * | 1993-06-02 | 2000-02-15 | Research Corporation Technologies, Inc. | Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same |
US6106834A (en) * | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
US6015555A (en) * | 1995-05-19 | 2000-01-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
US6893636B2 (en) * | 1997-02-20 | 2005-05-17 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US7033589B1 (en) * | 1997-02-20 | 2006-04-25 | Biogen Idec Ma Inc. | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
DE69835216T2 (de) | 1997-07-25 | 2007-05-31 | Nichia Corp., Anan | Halbleitervorrichtung aus einer nitridverbindung |
AUPP221098A0 (en) * | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
DK1100829T3 (da) * | 1998-07-27 | 2007-12-27 | Novartis Ag | Anvendelse af basiliximab til behandling af rheumatoid arthritis eller hudsygdomme |
US6406695B1 (en) | 1998-10-30 | 2002-06-18 | University Of Miami | Treatment of hepatitis C by administration of anti-IL-2 receptor monoclonal antibody |
WO2000025816A1 (en) * | 1998-10-30 | 2000-05-11 | The University Of Miami | Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound |
GB9825632D0 (en) | 1998-11-23 | 1999-01-13 | Novartis Ag | Organic compounds |
FR2793691B1 (fr) * | 1999-05-21 | 2003-10-03 | Hippocampe | Utilisation d'anticorps reconnaissant le recepteur de l'interleukine-2 dans la prevention et/ou le traitement des infections par les virus du sida |
GB0007911D0 (en) * | 2000-03-30 | 2000-05-17 | Novartis Ag | Organic compounds |
NZ528411A (en) * | 2001-04-06 | 2005-04-29 | Univ Bristol | Use of CD25 binding molecules in steroid-resistant patients and improving the response to steroid therapy in steroid-sensitive patients |
US7365168B2 (en) * | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7361740B2 (en) * | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
JP4033390B2 (ja) * | 2002-10-30 | 2008-01-16 | 独立行政法人科学技術振興機構 | 不死化ナチュラルキラー細胞株 |
PL217296B1 (pl) * | 2002-11-15 | 2014-07-31 | Genmab As | Wyizolowane ludzkie przeciwciało monoklonalne, wytwarzająca je hybrydoma, kodujący to przeciwciało wektor ekspresyjny i zawierająca je kompozycja farmaceutyczna, immunokoniugat, bispecyficzna lub multispecyficzna cząsteczka obejmująca kwasy nukleinowe kodujące ciężki i lekki łańcuch transfektoma, ich zastosowania, zwłaszcza w medycynie, obejmująca te kwasy ex vivo eukariotyczna lub prokariotyczna komórka gospodarza oraz nie będące człowiekiem zwierzę transgeniczne lub roślina, sposób in vitro hamowania wzrostu i/lub proliferacji komórek wyrażających CD25 lub eliminowania komórek wyrażających CD25, sposób wykrywania w próbce obecności antygenu CD25 lub komórki wyrażającej CD25, zestaw diagnostyczny do wykrywania w próbce obecności antygenu CD25 lub komórki wyrażającej CD25 |
EP1460088A1 (en) | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
JP2007531707A (ja) * | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ, インコーポレイテッド | IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変 |
CU23297A1 (es) * | 2004-11-16 | 2008-07-24 | Ct De Inmunologa A Molecular | Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer |
GB0507696D0 (en) * | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
ES2365046T3 (es) | 2005-12-30 | 2011-09-21 | Merck Patent Gmbh | Anticuerpos anti-cd19 con inmunogenicidad reducida. |
SG10201503135RA (en) | 2008-03-13 | 2015-06-29 | Biotest Ag | Agent for treating disease |
KR20100135257A (ko) | 2008-03-13 | 2010-12-24 | 바이오테스트 아게 | 질병 치료제 |
AU2009224690B2 (en) | 2008-03-13 | 2014-10-09 | Biotest Ag | Agent for treating disease |
EP4406615A2 (en) | 2009-10-26 | 2024-07-31 | F. Hoffmann-La Roche AG | Method for the production of a glycosylated immunoglobulin |
GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
WO2013087913A1 (en) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
KR101645905B1 (ko) | 2012-10-12 | 2016-08-04 | 스피로즌 살 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
EP3223854A1 (en) | 2014-11-25 | 2017-10-04 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
US9993452B2 (en) * | 2014-12-05 | 2018-06-12 | Vireo Systems, Inc. | Compositions and methods for treatment of inflammation |
WO2017096262A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
BR112019021680A2 (pt) | 2017-04-20 | 2020-05-12 | Adc Therapeutics Sa | Terapia de combinação com conjugado anticorpo-fármaco anti-cd25?? |
KR20210016562A (ko) | 2018-05-23 | 2021-02-16 | 에이디씨 테라퓨틱스 에스에이 | 분자 애쥬번트 |
GB201811364D0 (en) | 2018-07-11 | 2018-08-29 | Adc Therapeutics Sa | Combination therapy |
WO2020248938A1 (zh) * | 2019-06-10 | 2020-12-17 | 山东博安生物技术有限公司 | 抗cd25抗体及其应用 |
GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
US20230056336A1 (en) | 2021-04-15 | 2023-02-23 | Kyverna Therapeutics, Inc. | Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents |
CN114957473B (zh) * | 2022-04-25 | 2023-05-16 | 苏州旭光科星抗体生物科技有限公司 | 一种对可溶性cd25蛋白含量检测的酶联免疫检测试剂盒 |
WO2024006961A1 (en) | 2022-07-01 | 2024-01-04 | Neoleukin Therapeutics, Inc. | Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8605316D0 (en) * | 1986-03-04 | 1986-04-09 | Royal Free Hosp School Med | Immunosuppression |
GB2188941B (en) | 1986-04-14 | 1990-06-06 | Bayer Ag | Monoclonal antibodies recognizing human interleukin-2-receptor |
EP0319333B1 (en) * | 1987-12-02 | 1994-07-20 | Becton, Dickinson and Company | Method for the prevention of graft versus host disease |
EP0362371A4 (en) * | 1988-04-15 | 1990-10-24 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
DE3815472A1 (de) | 1988-05-06 | 1989-11-16 | Centre Regional De Transfusion | Monoklonaler antikoerper und seine verwendung |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US6013256A (en) | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
-
1991
- 1991-03-08 HU HU91761A patent/HUT60768A/hu unknown
- 1991-03-13 DE DE1991600768 patent/DE19975033I2/de active Active
- 1991-03-13 DK DK91810166.8T patent/DK0449769T3/da active
- 1991-03-13 AT AT91810166T patent/ATE98655T1/de active
- 1991-03-13 EP EP91810166A patent/EP0449769B1/en not_active Expired - Lifetime
- 1991-03-13 DE DE91810166T patent/DE69100768T2/de not_active Expired - Lifetime
- 1991-03-13 ES ES91810166T patent/ES2061216T3/es not_active Expired - Lifetime
- 1991-03-14 PT PT97034A patent/PT97034B/pt not_active IP Right Cessation
- 1991-03-14 CA CA002038279A patent/CA2038279C/en not_active Expired - Lifetime
- 1991-03-14 NZ NZ237434A patent/NZ237434A/en unknown
- 1991-03-14 AU AU72909/91A patent/AU635401B2/en not_active Expired
- 1991-03-14 US US07/669,545 patent/US6521230B1/en not_active Expired - Lifetime
- 1991-03-14 IL IL9754591A patent/IL97545A/xx active Protection Beyond IP Right Term
- 1991-03-14 FI FI911275A patent/FI103131B1/fi active Protection Beyond IP Right Term
- 1991-03-15 IE IE86791A patent/IE65062B1/en not_active IP Right Cessation
- 1991-03-15 PL PL91289436A patent/PL170321B1/pl unknown
- 1991-03-15 JP JP3076743A patent/JP2585475B2/ja not_active Expired - Lifetime
- 1991-03-19 TW TW080102143A patent/TW213486B/zh not_active IP Right Cessation
- 1991-09-05 MY MYPI91000340A patent/MY106161A/en unknown
-
1992
- 1992-01-27 SA SA92120358A patent/SA92120358B1/ar unknown
-
1995
- 1995-06-06 US US08/479,089 patent/US6383487B1/en not_active Expired - Fee Related
- 1995-06-15 HU HU95P/P00213P patent/HU211885A9/hu unknown
-
1997
- 1997-04-24 HK HK53797A patent/HK53797A/xx not_active IP Right Cessation
- 1997-09-05 CY CY197797A patent/CY1977A/xx unknown
-
1998
- 1998-08-21 FI FI981799A patent/FI104047B/fi active
-
1999
- 1999-04-01 NL NL990008C patent/NL990008I2/nl unknown
- 1999-04-07 LU LU90383C patent/LU90383I2/xx unknown
- 1999-08-23 FI FI991788A patent/FI19991788A/fi unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL97545A0 (en) | Monoclonal antibodies and other binding molecules against cd25 antigen | |
GB2246781A (en) | CD3 specific recombinant antibody | |
DK0626447T3 (da) | Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen | |
DE69429095D1 (de) | Humanisierte antikoerper | |
GR3020108T3 (en) | Monoclonal antibody reactive with a novel HLA determinant on MHC class I molecules and method for activating lymphocytes | |
UA29494C2 (uk) | Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція | |
CA2163989A1 (en) | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies | |
AU3933695A (en) | Humanized antibodies to CD38 | |
PL313260A1 (en) | Monoclonal antibodies having properties making them able to cause apoptosis | |
IL116617A0 (en) | Monoclonal antibodies specific for advanced glycosylation endproducts in biological samples | |
EP0499176A3 (en) | Monoclonal antibodies against human pancreatic islet cells | |
EP0338395A3 (en) | Monoclonal antibodies to pseudomonas aeruginosa, their production and use | |
KR930019820A (ko) | 모노클로날 항-강글리오사이드 항체, 이의 제조방법 및 종양 치료제로서의 용도 | |
MY104917A (en) | Monoclonal antibodies and methods for diagnosis of phytophora infection | |
GR3022544T3 (en) | Monoclonal antibodies to leptosphaeria | |
AU1626492A (en) | Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof | |
BG51639A1 (en) | Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody towards antigenous determinant of strain " hantaan " of the virus of haemorrhagic fever with nephritic syndrome | |
UA39209C2 (uk) | Моноклональне антитіло, що інгібує хомінг кровотворних стовбурових клітин і розпізнає поверхневий антіген стромальної клітини селезінки, гібридома, яка його продукує |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
PEL | Intention of commissioner to extend period of protection | ||
EXTG | Extension of patent term granted | ||
EXTG | Extension of patent term granted | ||
MM9K | Patent not in force due to non-payment of renewal fees | ||
EXTN | Extension order renewed | ||
KB | Patent renewed | ||
EXTN | Extension order renewed |